The central role of this pathway is highlighted by preclinical evidence showing that therapeutic agents like daphnetin can ameliorate inflammation by upregulating A20, reinforcing its position as a promising therapeutic target for SLE [329]. Here, TNFAIP3 is linked to systemic lupus erythematosus.